Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
The EXPLORE44 study enrolled DMD patients with DMD mutations amenable to exon 44 skipping (DMD44), a group that accounts for around 6% of all DMD cases in the US. It showed a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback